Immix Biopharma Inc (IMMX)

Jul 23, 2025

What analysts say about Immix Biopharma Inc. stockFree Stock Market Knowledge Sharing - Autocar Professional

Jul 23, 2025

Jul 23, 2025

Is Immix Biopharma Inc. a good long term investmentRecord-setting profit potential - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

Immix Biopharma Inc. Stock Analysis and ForecastUnrivaled growth potential - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

What drives Immix Biopharma Inc. stock priceTremendous wealth creation - jammulinksnews.com

Jul 22, 2025

Jul 17, 2025

What makes Immix Biopharma Inc. stock price move sharplyFree AI-Powered Stock Predictions - Newser

Jul 17, 2025

Jul 16, 2025

Why Immix Biopharma Inc. stock attracts strong analyst attentionHigh Yield Opportunities - Newser

Jul 16, 2025

Jul 15, 2025

How Immix Biopharma Inc. stock performs during market volatilityBreakout Level Watch - Newser

Jul 15, 2025

Jul 12, 2025

ImmixBio reports no neurotoxicity in CAR-T therapy for AL amyloidosis - Investing.com Nigeria

Jul 12, 2025

Jul 11, 2025

ImmixBio reports no neurotoxicity in CAR-T therapy for AL amyloidosis By Investing.com - Investing.com South Africa

Jul 11, 2025

Jul 11, 2025

Immix Biopharma Says NXC-201 Safety Profile Shows Absence of Neurotoxicity in Low-Volume Disease - MarketScreener

Jul 11, 2025

Jul 11, 2025

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion - MarketScreener

Jul 11, 2025

Jul 11, 2025

Immix Biopharma Reports Class-Leading Safety Profile for CAR-T NXC-201 in Low-Volume AL Amyloidosis, On Track for BLA Submission - Nasdaq

Jul 11, 2025

Jul 11, 2025

Revolutionary CAR-T Safety Data: IMMX Reports Zero Neurotoxicity in Rare Disease Treatment - Stock Titan

Jul 11, 2025

Jul 09, 2025

Immix Biopharma (NASDAQ:IMMX) Stock Price Up 1.5% – Here’s Why - Defense World

Jul 09, 2025

Jul 08, 2025

Immix Biopharma stock advances as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Nigeria

Jul 08, 2025

Jul 08, 2025

Immix Biopharma stock advances as H.C. Wainwright reiterates Buy rating - Investing.com

Jul 08, 2025

Jul 07, 2025

Immix Biopharma Expands NEXICART-2 Trial Sites Nationwide, Progressing Towards Biologics License Application for Cell Therapy in AL Amyloidosis - Nasdaq

Jul 07, 2025

Jul 07, 2025

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis - GlobeNewswire

Jul 07, 2025

Jul 07, 2025

Breakthrough Cell Therapy for AL Amyloidosis Accelerates Toward FDA Approval with 18 Trial Sites - Stock Titan

Jul 07, 2025

Jun 28, 2025

Immix Biopharma (NASDAQ:IMMX) Upgraded by Wall Street Zen to Hold Rating - Defense World

Jun 28, 2025

Jun 23, 2025

Immix Biopharma Holds Annual Meeting, Elects Directors - TipRanks

Jun 23, 2025

Jun 20, 2025

Immix Biopharma CEO Rachman buys $4998 in shares - Investing.com

Jun 20, 2025

Jun 10, 2025

Jane Street Group LLC Invests $39,000 in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World

Jun 10, 2025

Jun 10, 2025

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial - MSN

Jun 10, 2025

Jun 07, 2025

Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock? - MSN

Jun 07, 2025

Jun 07, 2025

Q3 EPS Estimates for Immix Biopharma Raised by HC Wainwright - Defense World

Jun 07, 2025